Tobacco Intervention in Buprenorphine Treatment (IBIS)

This study is currently recruiting participants.
Verified January 2013 by University of California, San Francisco
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Sharon Hall, University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01350011
First received: May 5, 2011
Last updated: January 29, 2013
Last verified: January 2013

May 5, 2011
January 29, 2013
April 2011
April 2014   (final data collection date for primary outcome measure)
Smoking Status [ Time Frame: 3, 6, 12, and 18 Months ] [ Designated as safety issue: No ]
Smoking status is defined as "no cigarettes for the past 7 days."
Same as current
Complete list of historical versions of study NCT01350011 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Tobacco Intervention in Buprenorphine Treatment
Extended Tobacco Dependence Intervention in Buprenorphine Treatment

Drug addiction treatment patients, including those in treatment for opioid dependence, have a high rate of tobacco dependence, especially cigarette smoking. The proposed study evaluates an Innovative System (IS) for the treatment of tobacco dependence in one group of opioid treatment patients, those in buprenorphine maintenance. The specific aims of the study are to test the efficacy and the cost effectiveness of the IS.

A secondary aim is obtain preliminary data about differences in use of non-nicotinic drugs between participants who achieve abstinence from cigarettes during the study, and those who do not.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Tobacco Dependence
  • Behavioral: Innovative System
    In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.
  • Behavioral: Standard Treatment Control (STC)
    Participants will receive self help information and referrals for counseling and for pharmacological treatment.
  • Active Comparator: Innovative System (IS)
    Intervention: Behavioral: Innovative System
  • Active Comparator: Standard Treatment Control
    Intervention: Behavioral: Standard Treatment Control (STC)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
April 2015
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All participants must smoke five or more cigarettes a day and be registered patients at Integrated Buprenorphine Intervention Services (IBIS) of the San Francisco Department of Public Health.

Exclusion Criteria:

  • Participants with contraindications to NRT will be excluded. Thus, participants who have had a myocardial infarction within the last three months, or who have uncontrolled high blood pressure will be excluded. We will exclude pregnant or nursing women.
  • Participants with contraindications to varenicline treatment will be included in the study but will not be eligible for varenicline treatment.
Both
18 Years and older
Yes
Contact: Gary L Humfleet, PhD 415-476-7674 ghumfleet@lppi.ucsf.edu
Contact: Sharon M Hall, PhD 415-476-7574 sharon.hall@ucsf.edu
United States
 
NCT01350011
P030871, P50DA009253
Yes
Sharon Hall, University of California, San Francisco
University of California, San Francisco
National Institute on Drug Abuse (NIDA)
Not Provided
University of California, San Francisco
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP